The Medical Letter on Drugs and Therapeutics
ONLINE
ONLY
ARTICLE
ONLY
ARTICLE
April 29, 2024
Tepotinib (Tepmetko) for NSCLC (online only)
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Tepotinib (Tepmetko) for NSCLC (online only)
April 29, 2024 (Issue: 1701)
The FDA has granted regular approval to the oral
kinase inhibitor tepotinib (Tepmetko – EMD Serono)
for treatment of adults with metastatic non-small
cell lung cancer (NSCLC) harboring mesenchymal-epithelial
transition (MET) exon 14...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.